<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04684446</url>
  </required_header>
  <id_info>
    <org_study_id>D8111C00003</org_study_id>
    <nct_id>NCT04684446</nct_id>
  </id_info>
  <brief_title>Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime-Boost Regimen for the Prevention of COVID-19</brief_title>
  <official_title>A Phase I/II Single-Blinded Randomized Safety and Immunogenicity Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime Boost Regimen for the Prevention of COVID 19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>R-Pharm</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Russian Direct Investment Fund</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Gamaleya National Center of Epidemiology &amp; Microbiology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>R-Pharm</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective is to evaluate the safety and immunogenicity of AZD1222 given in combination&#xD;
      with (either before or after) rAd26-S, for the prevention of COVID 19 in adults ≥ 18 years of&#xD;
      age.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 15, 2021</start_date>
  <completion_date type="Anticipated">April 8, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 8, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Single-blinded study</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Antibody seroconversion rate (≥ 4-fold increase from baseline) against SARS-CoV-2 neutralising antibodies 29 days post second vaccination.</measure>
    <time_frame>Day 29 through Day 57</time_frame>
    <description>Immunogenicity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of local and systemic solicited AEs for 7 days following each vaccination (Day 1 through Day 7 for first vaccination and Day 29 through Day 35 for second vaccination).</measure>
    <time_frame>Day 1 through Day 7 and Day 29 through Day 35</time_frame>
    <description>Safety</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of unsolicited AEs, SAEs and AESIs through 29 days post each vaccination (ie, until Day 29 following the first vaccination and Day 57 following the second vaccination).</measure>
    <time_frame>57 days</time_frame>
    <description>Safety</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of SAEs and AESIs after first vaccination until study end (Day 180).</measure>
    <time_frame>180 days</time_frame>
    <description>Safety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody seroconversion rate (≥ 4-fold increase from baseline) against SARS-CoV-2 Spike protein</measure>
    <time_frame>180 days</time_frame>
    <description>Immunogenicity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody seroconversion rate (≥ 4-fold increase from baseline) against RBD antigen.</measure>
    <time_frame>180 days</time_frame>
    <description>Immunogenicity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMT and GMFR of immunogenicity against Spike and RBD antigens (MSD serology assay) at the day of vaccination (baseline), Day 15, 29 days post each vaccination and at study end (Day 180).</measure>
    <time_frame>180 days</time_frame>
    <description>Immunogenicity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody seroconversion rate (≥ 4-fold increase from baseline) SARS-CoV-2 neutralising antibodies 29 days post first vaccination</measure>
    <time_frame>Day 1 through Day 29</time_frame>
    <description>Immunogenicity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMT and GMFR of immunogenicity as measured by SARS-CoV-2 neutralising antibodies at day of vaccination (baseline), Day 15, 29 days post each vaccination and at study end (Day 180).</measure>
    <time_frame>180 days</time_frame>
    <description>Immunogenicity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intracellular cytokine staining, including quantification of Th1/Th2 responses, and flow cytometry for B- and T-cell responses from day of dosing baseline to 29 days post each vaccination and until study end</measure>
    <time_frame>180 days</time_frame>
    <description>Safety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A binary response, whereby a participant is defined as a COVID-19 case if their illness (virologically confirmed [RT-PCR positive] and symptomatic) occurs</measure>
    <time_frame>Day 29 through Day 180</time_frame>
    <description>Efficacy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD1222 on Day 1 followed by rAd26-S on Day 29</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rAd26-S on Day 1 followed by AZD1222 on Day 29</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AZD1222</intervention_name>
    <description>Participants will receive 1 intramuscular (IM) injection of 5 ×1010 viral particles (vp) (nominal) of AZD1222 on Day 1 followed by rAd26-S 1×1011 viral particles (vp) (nominal) on Day 29 of the study</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rAd26-S</intervention_name>
    <description>Participants will receive 1 IM injection of rAd26-S on Day 1 followed by AZD1222 on Day 29</description>
    <arm_group_label>Arm 2</arm_group_label>
    <other_name>Sputnik V</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adults ≥ 18 years of age at the time of signing the informed consent&#xD;
&#xD;
          2. Overtly healthy as determined by medical evaluation, or&#xD;
&#xD;
             - Medically stable such that, according to the judgment of the investigator,&#xD;
             hospitalisation within the study period is not anticipated and the participant appears&#xD;
             likely to be able to remain in follow-up through the end of protocol-specified&#xD;
             follow-up.&#xD;
&#xD;
             o A stable medical condition is defined as disease not requiring significant change in&#xD;
             therapy or hospitalisation for worsening disease during the 3 months prior to&#xD;
             enrolment&#xD;
&#xD;
          3. Able to understand and comply with study requirements/procedures based on the&#xD;
             assessment of the investigator&#xD;
&#xD;
          4. Reproduction:&#xD;
&#xD;
        Female participants&#xD;
&#xD;
          1. Women of childbearing potential must:&#xD;
&#xD;
               -  Have a negative pregnancy test on the day of screening and on Day 1&#xD;
&#xD;
               -  Use one highly effective form of birth control for at least 28 days prior to Day&#xD;
                  1 and agree to continue using one highly effective form of birth control through&#xD;
                  60 days following administration of the second dose of study vaccine. A highly&#xD;
                  effective method of contraception is defined as one that can achieve a failure&#xD;
                  rate of less than 1% per year when used consistently and correctly.&#xD;
&#xD;
             Periodic abstinence, the rhythm method, and withdrawal are NOT acceptable methods of&#xD;
             contraception.&#xD;
&#xD;
          2. Women are considered of childbearing potential unless they meet either of the&#xD;
             following criteria:&#xD;
&#xD;
               -  Surgically sterilised (including bilateral tubal ligation, bilateral&#xD;
                  oophorectomy, or hysterectomy), or&#xD;
&#xD;
               -  Postmenopausal&#xD;
&#xD;
                  6. Capable of giving signed informed consent which includes compliance with the&#xD;
                  requirements and restrictions listed in the informed consent form (ICF) and in&#xD;
                  this protocol.&#xD;
&#xD;
             Exclusion Criteria:&#xD;
&#xD;
             Medical Conditions&#xD;
&#xD;
               1. Known past laboratory-confirmed SARS-CoV-2 infection.&#xD;
&#xD;
               2. Positive SARS-CoV-2 RT PCR test at screening.&#xD;
&#xD;
               3. Seropositivity to SARS-CoV-2 at screening.&#xD;
&#xD;
               4. Significant infection or other illness, including fever &gt; 37.8°C on the day prior&#xD;
                  to or on the day of randomization 5. Thrombocytopenia ≥ Grade 2 (i.e. &lt; 100&#xD;
                  000/mm^3) 6. Clinically significant neutropenia (as determined by the&#xD;
                  investigator). 7. Clinically significant anaemia (as determined by the&#xD;
                  investigator) 8. Any confirmed or suspected immunosuppressive or immunodeficient&#xD;
                  state; including human immunodeficiency virus (HIV) infection; asplenia;&#xD;
                  recurrent severe infections and use of chronic immunosuppressant medication&#xD;
                  (within the past 6 months(≥ 20 mg/day of prednisone or its equivalent, given&#xD;
                  daily or on alternate days for ≥ 15 days within 30 days prior to vaccination),&#xD;
                  except topical/inhaled steroids or short-term oral steroids ( course lasting ≤ 14&#xD;
                  days).&#xD;
&#xD;
             9. History of allergy to any component of the vaccine 10. Any history of anaphylaxis&#xD;
             or angioedema. 11. Current diagnosis of or treatment for cancer (except basal cell&#xD;
             carcinoma of the skin and uterine cervical carcinoma in situ).&#xD;
&#xD;
             12. History of serious psychiatric condition likely to affect participation in the&#xD;
             study.&#xD;
&#xD;
             13. Bleeding disorder (eg, factor deficiency, coagulopathy or platelet disorder), or&#xD;
             prior history of significant bleeding or bruising following IM injections or&#xD;
             venepuncture.&#xD;
&#xD;
             14 Suspected or known current alcohol or drug dependency. 15 History of Guillan-Barré&#xD;
             syndrome or any other demyelinating condition. 16 Any other significant disease,&#xD;
             disorder or finding which may significantly increase the risk to the participant&#xD;
             because of participation in the study, affect the ability of the participant to&#xD;
             participate in the study or impair interpretation of the study data.&#xD;
&#xD;
             17 Severe and/or uncontrolled cardiovascular disease, respiratory disease,&#xD;
             gastrointestinal disease, liver disease, renal disease, endocrine disorder and&#xD;
             neurological illness (mild/moderate well controlled comorbidities are allowed).&#xD;
&#xD;
             18. Prior splenectomy 19. History of cerebral venous sinus thrombosis or experienced&#xD;
             major venous and/or arterial thrombosis.&#xD;
&#xD;
             20. Receipt of any vaccine (licensed or investigational) other than the study&#xD;
             intervention within 30 days before and after each study vaccination.&#xD;
&#xD;
             21. Prior or planned receipt of an investigational or licensed vaccine or product&#xD;
             likely to impact on interpretation of the trial data (eg, adenovirus vectored&#xD;
             vaccines, any coronavirus vaccines).&#xD;
&#xD;
             22. Administration of immunoglobulins and/or any blood products within the 3 months&#xD;
             preceding the planned administration of the vaccine candidate.&#xD;
&#xD;
             23. Continuous use of anticoagulants, such as coumarins and related anticoagulants&#xD;
             (ie, warfarin) or novel oral anticoagulants (ie, apixaban, rivaroxaban, dabigatran and&#xD;
             edoxaban).&#xD;
&#xD;
             24. Participation in COVID-19 prophylactic drug trials for the duration of the study.&#xD;
&#xD;
             25. Involvement in the planning and/or conduct of the study (applies to both&#xD;
             AstraZeneca staff and/or staff at the study site).&#xD;
&#xD;
             26. Judgment by the investigator that the participant should not participate in the&#xD;
             study if the participant is unlikely to comply with study procedures, restrictions,&#xD;
             and requirements.&#xD;
&#xD;
             27. Previous randomisation in the present study 28. For female subjects only -&#xD;
             currently pregnant (confirmed with positive pregnancy test) or breastfeeding.&#xD;
&#xD;
             29. Unwilling to refrain from blood donation during the course of the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>130 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mikhail Samsonov</last_name>
    <role>Study Director</role>
    <affiliation>R-Pharm</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vitebsk Regional Clinical Hospital</name>
      <address>
        <city>Vitebsk</city>
        <zip>210037</zip>
        <country>Belarus</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sergey Pimanov</last_name>
      <phone>+375298996852</phone>
      <email>pimanovs@tut.by</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Joint-Stock Company &quot;Group of Companies Medsi&quot;</name>
      <address>
        <city>Moscow</city>
        <zip>109240</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Irina Shestakova</last_name>
      <phone>+79057692071</phone>
      <email>prof.shestakova@yandex.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>OJSC Clinical and Diagnostic Center Euromedservice</name>
      <address>
        <city>Moscow</city>
        <zip>115419</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Uruzmag Tomaev</last_name>
      <phone>+79683786656</phone>
      <email>umtomaev@mail.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <zip>121359</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>LLC PiterClinica</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>196158</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tatiana Pak</last_name>
      <phone>+79818518150</phone>
      <email>pte@list.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Federal State Budget Institution &quot;Scientific and Research Institute of Flu n.a. A.A. Smorodintseva&quot; of Ministry of Health of Russian Federation</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>197376</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dmitry Lioznov</last_name>
      <phone>+79219095103</phone>
      <email>dlioznov@yandex.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Federal State Budgetary Educational Institution of Higher Education &quot; First Saint Petersburg State Medical University named after Academician I. P. Pavlov&quot; of the Ministry of Healthcare of the Russian Federation</name>
      <address>
        <city>St. Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Svetlana Nikolaenko</last_name>
      <phone>+79213072831</phone>
      <email>nikolaenkos@yandex.ru</email>
    </contact>
  </location>
  <location_countries>
    <country>Belarus</country>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>December 23, 2020</study_first_submitted>
  <study_first_submitted_qc>December 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 24, 2020</study_first_posted>
  <last_update_submitted>September 20, 2021</last_update_submitted>
  <last_update_submitted_qc>September 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19 Prevention</keyword>
  <keyword>AZD1222 vaccine</keyword>
  <keyword>rAd26-S</keyword>
  <keyword>Sputnik V</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure</ipd_time_frame>
    <ipd_access_criteria>When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure</ipd_access_criteria>
    <ipd_url>https://astrazenecagroup-dt.pharmacm.com/DT/Home</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

